Correlation Between Enanta Pharmaceuticals and Novo Nordisk
Can any of the company-specific risk be diversified away by investing in both Enanta Pharmaceuticals and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enanta Pharmaceuticals and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enanta Pharmaceuticals and Novo Nordisk AS, you can compare the effects of market volatilities on Enanta Pharmaceuticals and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enanta Pharmaceuticals with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enanta Pharmaceuticals and Novo Nordisk.
Diversification Opportunities for Enanta Pharmaceuticals and Novo Nordisk
0.57 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Enanta and Novo is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Enanta Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enanta Pharmaceuticals are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Enanta Pharmaceuticals i.e., Enanta Pharmaceuticals and Novo Nordisk go up and down completely randomly.
Pair Corralation between Enanta Pharmaceuticals and Novo Nordisk
Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to under-perform the Novo Nordisk. In addition to that, Enanta Pharmaceuticals is 3.17 times more volatile than Novo Nordisk AS. It trades about -0.34 of its total potential returns per unit of risk. Novo Nordisk AS is currently generating about 0.04 per unit of volatility. If you would invest 10,909 in Novo Nordisk AS on September 12, 2024 and sell it today you would earn a total of 131.00 from holding Novo Nordisk AS or generate 1.2% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Enanta Pharmaceuticals vs. Novo Nordisk AS
Performance |
| Timeline |
| Enanta Pharmaceuticals |
| Novo Nordisk AS |
Enanta Pharmaceuticals and Novo Nordisk Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Enanta Pharmaceuticals and Novo Nordisk
The main advantage of trading using opposite Enanta Pharmaceuticals and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enanta Pharmaceuticals position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.| Enanta Pharmaceuticals vs. Equillium | Enanta Pharmaceuticals vs. DiaMedica Therapeutics | Enanta Pharmaceuticals vs. Valneva SE ADR | Enanta Pharmaceuticals vs. Vivani Medical |
| Novo Nordisk vs. Regeneron Pharmaceuticals | Novo Nordisk vs. Crispr Therapeutics AG | Novo Nordisk vs. Sarepta Therapeutics | Novo Nordisk vs. Intellia Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |